学科分类
/ 17
329 个结果
  • 简介:目的探讨青光眼术后颞侧小切口非超乳白内障摘除及人工晶状体植入术的疗效。方法对54例(72眼)青光眼滤过术后白内障患者采用颞上象限或颞侧小切口非超声乳化白内障摘除联合人工晶状体植入术,术后随访3~12个月,观察术后视力、眼压及并发症。结果65眼术后视力均有明显提高,7眼视力不变。术中、术后未见严重并发症,术后平均眼压(13.40±3.56)mmHg。功能性滤过泡保留完整,未见瘢痕化及渗漏。结论颞侧小切口非超乳白内障摘除及人工晶状体植入手术对青光眼术后白内障患者操作简单,视力提高明显,术后并发症少,眼压控制稳定。

  • 标签: 青光眼 白内障 人工晶体 小切口白内障手术
  • 简介:目的:分析玻璃体腔注射曲安奈德术后继发性青光眼的发生率和危险因素。方法:对连续收治的256例有玻璃体腔注射曲安奈德适应证的各类眼底病患者实施单次玻璃腔注射4mg/0.1mL曲安奈德手术,观察其术后眼压变化情况。主要适应证包括湿性年龄相关性黄斑变性,其它原因如糖尿病性视网膜病变、视网膜中央静脉阻塞、视网膜分支静脉阻塞,视网膜静脉周围炎等引起的黄斑水肿性疾病。结果:256例256眼经至少3mo的追踪观察随访中,56眼发生继发性青光眼,发病率为21.9%。结论:继发性青光眼与年龄、性别、血压、糖尿病、玻璃体腔注药术的不同适应证、术前是否行白内障手术、是否行光动力治疗、是否行玻璃体切除手术等因素没有相关性。注药前青光眼病史的存在和基础眼压高于19mmHg等情况为术后继发性青光眼的显著危险因素。

  • 标签: 曲安奈德 继发性青光眼 并发症
  • 简介:AIM:Toassesstheeffectivenessofimmunosuppressantsintheprophylaxisofcornealallograftrejectionafterhigh-riskkeratoplastyandnormal-riskkeratoplasty.METHODS:WesearchedtheCochraneCentralRegisterofControlledTrials(CENTRAL),MEDLINE,EMBASE,CNKI,VIPandreferencelistsofarticles.Dateofmostrecentsearch:18June,2011.Allrandomisedcontrolledtrials(RCTs)assessingtheuseofimmunosupressantsinthepreventionofgraftrejection,irrespectiveofpublicationlanguage.Twoauthorsassessedtrialqualityandextracteddataindependently.Onlydichotomousoutcomes(cleargraftsurvival,ratioofimmunereactionsandsideeffects)wereavailableandwereexpressedasrelativerisk(RR)and95%confidenceintervals(CI).RESULTS:Sevenstudieswereincludedinthisreview.Inthecomparingofmycophenolatemofetil(MMF)withplacebo,theresultsshowedMMFcouldsignificantlyreduceimmunereactionscomparedwithplacebo(RR1.0895%Cl0.95to1.21),butnoeffectoncleargraftsurvival(RR1.1195%Cl0.90to1.35).Incleargraftsurvivalandimmunereactions,MMFandcyclosporineA(CsA)showedsimilareffect(RR1.1195%Cl0.90to1.35,andRR1.48,95%Cl0.56to3.93,respectively).Tacrolimus(FK506)andsteroidshowedsimilareffectsoncleargraftsurvivalandimmunereactions(RR0.32,95%CI0.02to6.21,andRR1.00,95%CI0.88to1.14,respectively).Nodrugrelativesideeffecthasbeenfound.CONCLUSION:MMFmayreduceimmunereactionsinbothnormal-riskandhigh-riskrejectionofpenetratingkeratoplasty.CsAandFK506showedsimilareffectsasMMF.However,duetothelackoflargeclinicaltrials,theevidenceremainweak,thequalityofevidenceswereratedasverylowtomoderate.Large,properlyrandomised,placebo-controlled,doublemaskedtrialsareneededtoevaluatetheeffectofimmunosuppressants.

  • 标签: IMMUNOSUPPRESSANTS PENETRATING KERATOPLASTY META-ANALYSIS
  • 简介:目的观察泪道探通后氟尿嘧啶应用联合鼻泪管中逆行植入球头硅胶管术治疗慢性泪囊炎的临床疗效。方法从门诊就诊的泪道阻塞患者中,选取泪点泪小管均通畅的慢性泪囊炎患者42例(56只眼),随机分为实验组与对照组,治疗组采用先泪道探通扩张,并将氟尿嘧啶溶液浸入阻塞创面,后经鼻腔逆行植入球头硅胶管术治疗,对手术疗效进行分析。对照组则不采用氟尿嘧啶干预措施,其余治疗与对照组相同。两组患者均于术后3个月拔管。结果拔管后随访3~12个月,治疗组21例(29只眼)中有效25只眼,泪道冲洗通畅无分泌物,2只眼冲洗欠通畅无分泌物,2眼泪道冲洗仍阻塞,治愈率86.2%。对照组21例(27只眼)中有效17只眼,泪道冲洗通畅无分泌物,4只眼冲洗欠通畅无分泌物,6眼泪道冲洗仍阻2塞,治愈率63.0%。经χ检验治疗组治愈率高于对照组(P〈0.05)。结论泪道探通联合球头硅胶管逆行植入术治疗慢性泪囊炎具有操作简便、不切皮肤、不损伤组织结构等优点,临床疗效肯定。氟尿嘧啶对于预防泪道阻塞部位创面再次粘连,提高远期疗效有确切作用。

  • 标签: 慢性泪囊炎 氟尿嘧啶 球头硅胶管
  • 简介:目的观察Ex-press青光眼引流器植入术治疗难治性青光眼患者的疗效及安全性。方法选取2015年月—520177月我院难治性青光眼患者74例(74眼),依据治疗方案不同分组,各37例(37眼)。观察组行Ex-press青光眼引流器植入术,对照组行小梁切除术。统计对比两组手术成功率及并发症发生情况。结果观察组手术成功率.49%(32/较对8637)照组59.46%(22/37)高,且并发症发生率18.92%(7/37)较对照组40.54%(15/37)低,差异有统计学意义(P〈0.05)。结论Ex-press青光眼引流器植入术应用于难治性青光眼治疗中,可进一步提高治疗效果,且安全性较高。

  • 标签: 难治性青光眼 Ex-press青光眼引流器植入术 安全性
  • 简介:AIM:Toinvestigatetheaccuracyofintraocularpressure(IOP)asmeasuredbyaReichertOcularResponseAnalyzer(ORA),aswellastherelationshipbetweencentralcornealthickness(CCT)andIOPasmeasuredbyORA,Goldmannapplanationtonometry(GAT),anddynamiccontourtonometry(DCT).·METHODS:Atotalof158healthyindividuals(296eyes)werechosenrandomlyformeasurementofIOP.AfterCCTwasmeasuredusingA-ultrasound(A-US),IOPwasmeasuredbyORA,GAT,andDCTdevicesinarandomizedorder.TheIOPvaluesacquiredusingeachofthethreetonometrieswerecompared,andtherelationshipbetweenCCTandIOPvalueswereanalyzedseparately.TwoIOPvalues,Goldmann-correlatedIOPvalue(IOPg)andcorneal-compensatedintraocularpressure(IOPcc),weregotusingORA.ThreegroupsweredefinedaccordingtoCCT:1)thincornea(CCT<520μm);2)normal-thicknesscornea(CCT:520-580μm);and3)thickcornea(CCT>580μm)groups.·RESULTS:Innormalsubjects,IOPmeasurementswere14.95±2.99mmHgwithORA(IOPg),15.21±2.77mmHgwithORA(IOPcc),15.22±2.77mmHgwithGAT,and15.49±2.56mmHgwithDCT.Meandifferenceswere0.01±2.29mmHgbetweenIOPccandGAT(P>0.05)and0.28±2.20mmHgbetweenIOPccandDC(P>0.05).TherewasagreatercorrelationbetweenIOPccandDCT(r=0.946,P=0.000)thanthatbetweenIOPccandGAT(r=0.845,P=0.000).DCThadasignificantcorrelationwithGAT(r=0.854,P=0.000).GATwasmoderatelycorrelatedwithCCT(r=0.296,P<0.001),whileIOPccshowedaweakbutsignificantcorrelationwithCCT(r=0.155,P=0.007).TherewasastrongnegativecorrelationbetweenCCTandthedifferencebetweenIOPccandGAT(r=-0.803,P=0.000),withevery10increaseinCCTresultinginanincreaseinthisdifferenceof0.35mmHg.Thethickcorneagroup(CCT>580μm)showedtheleastsignificantcorrelationbetweenIOPccandGAT(r=0.859,P=0.000);whilethethincorneagroup(CCT<520μm)hadthemostsignificantcorrelationbetweenIOPccandGAT(r=0.926,P=0.000).ThecorrelateddifferencesbetweenIOPccan

  • 标签: INTRAOCULAR PRESSURE TONOMETRY CENTRAL CORNEAL thickness
  • 简介:AIM:ToIntroduceanewspecializedvisualacuitychartforamblyopicchildrenaged3-5yearsoldanditsclinicalapplications.METHODS:ThenewvisualacuitychartandnotationsweredesignedbasedonWeber-Fechnerlaw.Theoptotypeswereredagainstawhitebackgroundandwerespeciallyshapedfourbasicgeometricsymbols:circle,square,triangle,andcross.Aregulargeometricprogressionoftheoptotypesizesanddistributionwasemployedtoarrangein14lines.Theprogressionrateoftheoptotypesizebetweentwolineswas1.2589andthetestingdistancewas3m.VisualacuityscorecouldberecordedaslogMARnotationordecimalnotation.Agestratifieddiagnosticcriteriaforamblyopiaestablishedbyconsensusstatementondiagnosisofamblyopia(2011)amongmembersoftheStrabismusandPediatricOphthalmologyGroup,OphthalmologySociety,ChineseMedicalAssociation(SPOGOSCMA)wereillustratedinthenewvisualacuitychart.RESULTS:Whenassessingvisualacuityinchildrenaged3-5yearsold,thisnewvisualacuitychartthatconsistsoffoursymmetricalshapes(triangle,square,cross,andcircle)overcameaninabilitytorecognizethelettersofthealphabetanddifficultiesindesignatingthedirectionofblackabstractsymbolssuchasthetumbling’E’orLandolt’C’,whichthesubjectswerepronetoloseinterestin.Thevisualacuityscoremayberecordedindifferentnotations:decimalacuityandlogMAR.Thesetwonotationscanbeeasilyconvertedeachotherintheneweyechart.Themeasurementsofthisnewchartnotonlyshowedasignificantcorrelationandagoodconsistencywiththeinternationalstandardlogarithmicvisualacuitychart(r=0.932,P<0.01),butalsoindicatedahightest-retestreliability(89%ofretestscoreswerewithin0.1logMARunitsoftheinitialtestscore).CONCLUSION:Theresultsofthisstudysupportthevalidityandreliabilityofdistancevisualacuitymeasurementsusingtheneweyechartinchildrenaged3to5yearsoverawiderangeofvisualacuities,andtheneweyechartisgreatforearl

  • 标签: amblyopic CHILDREN Weber-Fcchner LAW INTERNATIONAL standard
  • 简介:目的:通过测定糖尿病性白内障患者血清中糖代谢指标、胰岛素抵抗与房水和血清中炎症因子的水平,探讨其相关性。方法:随机选取我院2017-02/2018-01糖尿病性白内障患者69例(观察组)和白内障患者65例(对照组),检测两组患者血清中糖化血红蛋白(HbA1c)、空腹血糖(FPG)、空腹胰岛素(FINS)的水平,计算胰岛素抵抗指数(HOMA-IR);同时检测房水和血清中的胰岛素样生长因子-1(IGF-1)、白细胞介素-6(IL-6)含量,对HbA1c、HOMA-IR与房水和血清中IGF-1、IL-6含量进行相关性分析。结果:对照组血清中的FPG、HbA1c、HOMA-IR,以及房水和血清中IGF-1、IL-6含量显著低于观察组,差异有统计学意义(均P<0.05)。HbA1c与房水及血清中的IGF-1和IL-6均呈正相关(P<0.05)。HOMA-IR与房水及血清中的IGF-1和IL-6均呈正相关(P<0.05)。结论:糖尿病性白内障患者HbA1c、HOMA-IR与房水及血清中的IGF-1、IL-6含量具有相关性,通过对上述指标的测定可以辅助判断病情。

  • 标签: 糖尿病性白内障 胰岛素抵抗 房水 胰岛素样生长因子-1 白细胞介素-6
  • 简介:目的:系统评价拉坦前列素(Latanoprost)滴眼液与噻吗心安(Timolol)滴眼液降眼压的有效性和安全性。方法:计算机检索PubMed,Medline,CNKI及中国生物医学文献数据库收录的,并辅以手工检索、因特网搜索的有关拉坦前列素与噻吗心安治疗原发性开角型青光眼和高眼压症的随机对照试验(RCT)。按照纳入和排除标准限定研究对象,通过Jadad评分量表进行文献质量评估后,针对眼压下降比例、药物不良反应2项内容,使用Cochrane协作网提供的RevMan5.0软件进行Meta分析。结果:共纳入9项RCT,合计555例患者。Meta分析结果显示:(1)拉坦前列素滴眼液与噻吗心安滴眼液降眼压效果,在2,6,12wk时差异均有统计学意义(P<0.01),加权平均差(WMD)分别为:在2wk[WMD=-0.76,95%CI(-1.32,-0.20)],在6wk[WMD=-1.15,95%CI(-1.68,0.63)]和12wk[WMD=-1.01,95%CI(-1.42,-0.61)]。(2)随访结束时,结膜充血、异物感为拉坦前列素的两种较为常见的不良反应,但其发生率拉坦前列素组与噻吗心安组比较,结膜充血的发生率[OR=2.25,95%CI(0.99,5.08)],异物感的发生率[OR=2.48,95%CI(1.02,6.03)],显示二者差异均无统计学意义。结论:治疗原发性开角型青光眼和高眼压症,拉坦前列素降眼压效果在用药12wk内较噻吗心安好;两者在12wk内引起结膜充血、异物感、虹膜色素加深、视野损害等的不良反应方面,差异不明显。由于纳入研究的样本量偏小,且方法学质量中等,致使本系统评价结果论证强度不高,因此还需要开展更多的高质量的临床随机对照研究,以便更客观、准确、全面地评价其疗效和安全性。

  • 标签: 拉坦前列素 噻吗心安 原发性开角型青光眼 高眼压症 有效性 安全性